Yuman Fong, MD

Department of Surgery, City of Hope Medical Center, Duarte, CA, USA

Dr. Yuman Fong received a BA in medieval literature from Brown University in 1981, and an MD from Cornell University Medical College in 1984. This was followed by surgical training at the New York Hospital/Cornell Medical Center under Dr. G. Thomas Shires, a research fellowship under Dr. Stephen Lowry, and a surgical oncology fellowship with Dr. Murray F. Brennan at the Memorial Sloan-Kettering Cancer Center. For over twenty years, he was an attending surgeon at the Memorial Sloan-Kettering Cancer Center (MSKCC), where he held the Murray F. Brennan Chair in Surgery, and was a Professor of Surgery at Weill Cornell Medical College. He recently relocated to Southern California, where he is the Chairman of the Department of Surgery at the City of Hope Medical Center.

Dr. Fong is best known clinically for his extensive work in the field of hepatobiliary surgery––especially for hepatocellular carcinoma, hepatic metastases from colorectal cancer, gallbladder cancer, and cholangiocarcinoma. He has pioneered many surgical, laparoscopic, robotic and ablative therapies for these cancers that occur in over a million people yearly worldwide. Nationally and internationally, he has also participated in and coordinated many studies aimed at understanding, preventing, and treating these cancers. In particular, he is focused on developing low cost and minimally invasive treatments for these cancers.

Dr. Fong leads an active laboratory studying the use of genetically modified viruses for the killing of cancer. He was one of the first investigators to administer engineered viruses into the blood stream of humans for treatment of cancer. He is active at coordinating trials of such novel viruses in international clinical trials. He has co-authored over 600 peer reviewed articles and 11 text books.

He is a member of numerous of scientific and medical societies including the American Surgical Association, Southern Surgical Association, and American Society for Clinical Investigation. He has served on the editorial boards of 14 journals. He is currently Editor in Chief of Molecular Therapy Oncolytics (Nature Publishing). He has received many honors and awards including the James IV Surgical Traveler, and the Shipley Award from the Southern Surgical Association. He has served on the board of the Society for Surgery of the Alimentary Tract and the board of the James IV Society of Surgeons. He has been Chair of the Gastrointestinal Organ Site Committee of the ACS Oncology Group, and Chair of the recombinant DNA advisory committee of the National Institutes of Health.